Expand MNKD Menu
MNKD MENU

MNKD Latest Press Releases

-- June 23, 2026 --

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza in Youth with Newly-Diagnosed T1D Globe Newswire 9:00 AM

-- June 5, 2026 --

Data at ADA 2026 Highlights Key Findings from Clinical and Real-World Studies of MannKind's Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems Globe Newswire 7:35 PM

-- June 3, 2026 --

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF Globe Newswire 6:05 AM

-- May 29, 2026 --

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval Globe Newswire 2:00 PM
MannKind Announces FDA Approval of Afrezza, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes Globe Newswire 12:30 PM

-- May 27, 2026 --

MannKind to Present at Jefferies Global Healthcare Conference Globe Newswire 4:00 PM
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems Globe Newswire 9:05 AM

-- May 6, 2026 --

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:01 PM
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases Globe Newswire 6:30 AM

-- April 29, 2026 --

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 Globe Newswire 4:01 PM

-- March 9, 2026 --

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza at ATTD 2026 Globe Newswire 9:05 AM

-- March 5, 2026 --

MannKind Announces Settlement of Convertible Senior Notes Globe Newswire 4:30 PM

-- March 4, 2026 --

MannKind to Participate in Upcoming Investor Conferences Globe Newswire 9:00 AM

-- February 26, 2026 --

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 8:00 AM

-- February 19, 2026 --

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference Globe Newswire 9:00 AM

-- February 18, 2026 --

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 Globe Newswire 9:00 AM

-- February 9, 2026 --

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) Globe Newswire 6:05 AM
Market Data Delayed 15 Minutes